S1 vs Pathway Expression



	IC(Δ)	P-val	FDR
BOYAULT_LIVER_CANCER_SUBCLASS_G6	0.521(0.021)	2.62e-06	3.77e-04
COLDREN_GEFITINIB_RESISTANCE	0.519(0.018)	2.62e-06	3.77e-04
ONDER_CDH1_TARGETS_2	0.495(0.020)	2.62e-06	3.77e-04
ESC_J1_UP_LATE.V1_DN	0.494(0.026)	2.62e-06	3.77e-04
MOHANKUMAR_TLX1_TARGETS	0.492(0.018)	2.62e-06	3.77e-04
EIF4E	0.473(0.016)	2.62e-06	3.77e-04
DAVIES_MULTIPLE_MYELOMA_VS_MGUS	0.467(0.018)	2.62e-06	3.77e-04
JAEGER_METASTASIS	0.459(0.018)	2.62e-06	3.77e-04
NIELSEN_SYNOVIAL_SARCOMA	0.448(0.021)	2.62e-06	3.77e-04
ROESSLER_LIVER_CANCER_METASTASIS	0.444(0.028)	2.62e-06	3.77e-04
PDGF_UP.V1	0.443(0.019)	2.62e-06	3.77e-04
TAUBE_EMT	0.443(0.022)	2.62e-06	3.77e-04
BOYLAN_MULTIPLE_MYELOMA_C_D	0.441(0.024)	2.62e-06	3.77e-04
PID_LKB1_PATHWAY	0.430(0.024)	2.62e-06	3.77e-04
GROGER_EMT	0.430(0.019)	2.62e-06	3.77e-04
COLDREN_GEFITINIB_RESISTANCE_UP	0.429(0.021)	2.62e-06	3.77e-04
WOOD_EBV_EBNA1_TARGETS	0.428(0.025)	2.62e-06	3.77e-04
ONDER_CDH1_TARGETS_3	0.427(0.016)	2.62e-06	3.77e-04
BILANGES_RAPAMYCIN_SENSITIVE_VIA_TSC1_AND_TSC2	0.425(0.026)	2.62e-06	3.77e-04
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC	0.423(0.021)	2.62e-06	3.77e-04
JAEGER_METASTASIS_DN	-0.508(0.018)	2.62e-06	4.54e-05
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN	-0.510(0.018)	2.62e-06	4.54e-05
ONDER_CDH1_TARGETS_2_DN	-0.511(0.018)	2.62e-06	4.54e-05
BIOCARTA_IL7_PATHWAY	-0.512(0.019)	2.62e-06	4.54e-05
ONDER_CDH1_TARGETS_3_DN	-0.513(0.019)	2.62e-06	4.54e-05
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP	-0.513(0.016)	2.62e-06	4.54e-05
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_DN	-0.513(0.015)	2.62e-06	4.54e-05
P53_DN.V1_UP	-0.514(0.022)	2.62e-06	4.54e-05
LANDIS_BREAST_CANCER_PROGRESSION_UP	-0.521(0.020)	2.62e-06	4.54e-05
REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS	-0.524(0.016)	2.62e-06	4.54e-05
MCBRYAN_PUBERTAL_BREAST_4_5WK_UP	-0.526(0.020)	2.62e-06	4.54e-05
KOYAMA_SEMA3B_TARGETS	-0.529(0.017)	2.62e-06	4.54e-05
MCBRYAN_PUBERTAL_BREAST_5_6WK_UP	-0.530(0.016)	2.62e-06	4.54e-05
MCBRYAN_PUBERTAL_BREAST_5_6WK	-0.532(0.017)	2.62e-06	4.54e-05
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP	-0.533(0.022)	2.62e-06	4.54e-05
COLDREN_GEFITINIB_RESISTANCE_DN	-0.540(0.021)	2.62e-06	4.54e-05
BOYAULT_LIVER_CANCER_SUBCLASS_G6_DN	-0.545(0.018)	2.62e-06	4.54e-05
ROESSLER_LIVER_CANCER_METASTASIS_DN	-0.545(0.018)	2.62e-06	4.54e-05
MURATA_VIRULENCE_OF_H_PILORI	-0.555(0.019)	2.62e-06	4.54e-05
IMMUNOLOGICAL_SYNAPSE	-0.561(0.022)	2.62e-06	4.54e-05